Sutro Biopharma, Inc
111 Oyster Point Blvd
South San Francisco
California
94080
United States
Tel: 650.881.6500
Website: http://www.sutrobio.com/
Email: general@sutrobio.com
About Sutro Biopharma, Inc
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
Stock Symbol: STRO
Bill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV – “Sutro Biopharma’s CEO on ADCs, non-cell protein synthesis, and more" - view it here
Our Sutro Story
196 articles about Sutro Biopharma, Inc
-
Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer
4/20/2021
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced the promotion of Chief Scientific Officer Trevor Hallam, Ph.D., to President of Research.
-
Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
4/15/2021
- Initiation of an IND enabling toxicology study for the first program under the 2018 collaboration on cytokine derivatives earns a $15 million milestone payment from Merck
-
Sutro Biopharma to Present at Two Upcoming Investor Conferences
4/8/2021
Sutro Biopharma, Inc. , today announced that Chief Executive Officer, Bill Newell , will present at two upcoming investor conferences
-
BioSpace Movers & Shakers, March 26
3/26/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
3/22/2021
Sutro Biopharma, Inc. announced the strengthening of key leadership roles including the promotion of David Pauling, J.D., M.A., to General Counsel, the promotion of Robert Kiss, Ph.D., to Senior Vice President, Process and Analytical Development, and the appointment of Ana Oaknin Benzaquen, M.D., Ph.D., to Sutro's Clinical Advisory Board.
-
Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones
3/18/2021
- Year-end 2020 cash, cash equivalents and marketable securities of $326.5 million, with projected runway into the second half of 2023 - Four antibody-drug conjugate programs are now in the clinic that were discovered through Sutro's proprietary and integrated cell-free protein synthesis platform
-
Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference
2/23/2021
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Bill Newell , Chief Executive Officer, will participate in the Ovarian Cancer Panel discussion on March 2, 2021
-
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
1/21/2021
Sutro Biopharma, Inc. today announced the dosing of the first patient in the dose-expansion cohort of Phase 1 study.
-
While Sutro’s technological platform opens multiple therapeutic doors, the company’s singular focus on homogeneous molecules is a key part of its competitive strategy.
-
Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
1/5/2021
Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, Jan. 14, 2021 at 5:20 p.m. ET / 2:20 p.m. PT.
-
Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares
12/11/2020
Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the closing of its upsized public offering of 6,900,00
-
Sutro Biopharma Announces Pricing of $126.0 Million Public Offering
12/8/2020
Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the pricing of an underwritten public offering of 6,000,000
-
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
12/7/2020
- STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular or neuropathy toxicity signals; MTD has not been reached - - 1 CR & 2 PRs observed in heavily pretreated patients with DLBCL; 1 SD in marginal zone lymphoma; 2 SDs in follicular lymphoma - Fred Hutchinson preclinical models with STRO-001 identifies CD74 as a potential target for the treatment of AML
-
Sutro Biopharma Announced Proposed Public Offering of 5 Million Shares of Common Stock
12/7/2020
Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced a proposed underwritten public offering in which it int
-
As the dose of Sutro Biopharma’s ovarian cancer drug, STRO-002, increased in an ongoing Phase I dose-escalation trial, survival rates have also increased.
-
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12/3/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today provided a clinical update from the company's ongoing dose-escalation Phase 1 study of STRO-002
-
Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors
12/1/2020
- Dr. Wigginton, leader in immuno-oncology and CMO at Cullinan Oncology, to bring additional strategic expertise to Sutro's Board -
-
Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
11/24/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-gene
-
Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
11/18/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, announced today the appointment of two executives to the Company's leadership team.
-
Sutro Biopharma to Participate in Four Upcoming Investor Conferences
11/11/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, today announced that Chief Executive Officer, Bill Newell , will participate in four upcoming virtual conferences in November and December of 2020. Presentations Details: 2020 Stifel Virtual Health